Intellia Therapeutics Inc (NTLA) Trading Down 5.9%
Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price fell 5.9% during mid-day trading on Wednesday . The stock traded as low as $22.70 and last traded at $23.05, with a volume of 537,584 shares changing hands. The stock had previously closed at $24.50.
Several brokerages have recently issued reports on NTLA. Wedbush began coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price target on the stock. Jefferies Group started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “hold” rating and a $33.00 price objective for the company. Credit Suisse Group AG started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective for the company. Leerink Swann started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Zacks Investment Research lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $35.50.
The company’s market capitalization is $758.77 million. The firm has a 50 day moving average of $19.32 and a 200-day moving average of $23.08.
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.